Quantum Black Hole in the Generalized Uncertainty Principle Framework

In this paper we study the effects of the Generalized Uncertainty Principle (GUP) on canonical quantum gravity of black holes. Through the use of modified partition function that involves the effects of the GUP, we obtain the thermodynamical properties of the Schwarzschild black hole. We also calculate the Hawking temperature and entropy for the modification of the Schwarzschild black hole in the presence of the GUP.Comment: 11 pages, no figures, to appear in Physical Review

Braneworld stars and black holes

We look for spherically symmetric star or black hole solutions on a Randall-Sundrum brane from the perspective of the bulk. We take a known bulk solution, and analyse possible braneworld trajectories within it that correspond, from the braneworld point of view, to solutions of the brane Tolman-Oppenheimer-Volkoff equations. Our solutions are therefore embedded consistently into a full bulk solution. We find the full set of static gravitating matter sources on a brane in a range of bulk spacetimes, analyzing which can correspond to physically sensible sources. Finally, we look at time-dependent trajectories in a Schwarzschild--anti de Sitter spacetime as possible descriptions of time-dependent braneworld black holes, highlighting some of the general features one might expect, as well as some of the difficulties involved in getting a full solution to the question.Comment: 39 pages, 15 figure

Discovering sequences with potential regulatory characteristics

AbstractWe developed a computational model to explore the hypothesis that regulatory instructions are context dependent and conveyed through specific ‘codes’ in human genomic DNA. We provide examples of correlation of computational predictions to reported mapped DNase I hypersensitive segments in the HOXA locus in human chromosome 7. The examples show that statistically significant 9-mers from promoter regions may occur in sequences near and upstream of transcription initiation sites, in intronic regions, and within intergenic regions. Additionally, a subset of 9-mers from coding sequences appears frequently, as clusters, in regulatory regions dispersed in noncoding regions in genomic DNA. The results suggest that the computational model has the potential of decoding regulatory instructions to discover candidate transcription factor binding sites and to discover candidate epigenetic signals that appear in both coding and regulatory regions of genes

In-situ characterization of the Hamamatsu R5912-HQE photomultiplier tubes used in the DEAP-3600 experiment

The Hamamatsu R5912-HQE photomultiplier-tube (PMT) is a novel high-quantum efficiency PMT. It is currently used in the DEAP-3600 dark matter detector and is of significant interest for future dark matter and neutrino experiments where high signal yields are needed. We report on the methods developed for in-situ characterization and monitoring of DEAP's 255 R5912-HQE PMTs. This includes a detailed discussion of typical measured single-photoelectron charge distributions, correlated noise (afterpulsing), dark noise, double, and late pulsing characteristics. The characterization is performed during the detector commissioning phase using laser light injected through a light diffusing sphere and during normal detector operation using LED light injected through optical fibres

Abatement of styrene waste gas emission by biofilter and biotrickling filter: comparison of packing materials and inoculation procedures

The removal of styrene was studied using 2 biofilters packed with peat and coconut fibre (BF1-P and BF2-C, respectively) and 1 biotrickling filter (BTF) packed with plastic rings. Two inoculation procedures were applied: an enriched culture with strain Pseudomonas putida CECT 324 for biofilters and activated sludge from a municipal wastewater treatment plant for the BTF. Inlet loads (ILs) between 10 and 45 g m-3 h-1 and empty bed residence times (EBRTs) from 30 to 120 s were applied. At inlet concentrations ranging between 200 and 400 mg Nm-3, removal efficiencies between 70 and 95% were obtained in the 3 bioreactors. Maximum elimination capacities (ECs) of 81 and 39 g m-3 h-1 were obtained for the first quarter of the BF1-P and BF2-C, respectively (IL of 173 g m-3 h-1 and EBRT of 60 s in BF1-P; IL of 89 g m-3 h-1 and EBRT of 90 s in BF2-C). A maximum EC of 52 g m-3 h-1 was obtained for the first third of the BTF (IL of 116 g m-3 h-1, EBRT of 45 s). Problems regarding high pressure drop appeared in the peat biofilter, whereas drying episodes occurred in the coconut fibre biofilter. DGGE revealed that the pure culture used for biofilter inoculation was not detected by day 105. Although 2 different inoculation procedures were applied, similar styrene removal at the end of the experiments was observed. The use as inoculum of activated sludge from municipal wastewater treatment plant appears a more feasible option

Analisis Sifat Fisika dan Derajat Keasaman terhadap Kualitas Air Minum Isi Ulang 20 Rumah RW 01 di Kampung Cilember Desa Jogjogan Kecamatan Cisarua Kabupaten Bogor

Air merupakan sumber daya alam yang berperan penting dalam kehidupan setelah udara, salah satu peran terpentingnya adalah untuk dikonsumsi. Namun, permasalahan yang sering terjadi adalah kurangnya pengetahuan masyarakat tentang kualitas air minum khususnya isi ulang yang dikonsumsi. Tujuan dari penelitian ini adalah untuk menganalisis kualitas air minum isi ulang beberapa Rumah di RW 01 Kampung Cilember Desa Jogjogan Kecamatan Cisarua Kabupaten Bogor terhadap hasil uji sifat fisika dan derajat keasamannya. Metode penelitian yang dilakukan dalam pengambilan sampel air minum adalah metode sampel gabungan tempat atau integrated sampel, terdapat 20 rumah warga dilakukan pengambilan sampel air untuk diukur kualitas secara fisika (warna, bau, rasa, TDS dan suhu) dan secara kimia (pH atau derajat keasaman). Berdasarkan hasil pengujian, terdapat 5 rumah yang memenuhi standar kualitas air minum isi ulang dari 20 rumah warga yang diuji. Hal tersebut dapat dilihat dari parameter standar yang berlaku dengan kisaran pH antara 6,5-8,5, TDS rata-rata 600-900 ppm, suhu ±3oC suhu udara, serta tidak memiliki bau, rasa, dan warna

Impact of the Covid-19 pandemic on perinatal mental health (Riseup-PPD-COVID-19): protocol for an international prospective cohort study

Background: Corona Virus Disease 19 (COVID-19) is a new pandemic, declared a public health emergency by the World Health Organization, which could have negative consequences for pregnant and postpartum women. The scarce evidence published to date suggests that perinatal mental health has deteriorated since the COVID-19 outbreak. However, the few studies published so far have some limitations, such as a cross-sectional design and the omission of important factors for the understanding of perinatal mental health, including governmental restriction measures and healthcare practices implemented at the maternity hospitals. Within the Riseup-PPD COST Action, a study is underway to assess the impact of COVID-19 in perinatal mental health. The primary objectives are to (1) evaluate changes in perinatal mental health outcomes; and (2) determine the risk and protective factors for perinatal mental health during the COVID-19 pandemic. Additionally, we will compare the results between the countries participating in the study. Methods: This is an international prospective cohort study, with a baseline and three follow-up assessments over a six-month period. It is being carried out in 11 European countries (Albania, Bulgaria, Cyprus, France, Greece, Israel, Malta, Portugal, Spain, Turkey, and the United Kingdom), Argentina, Brazil and Chile. The sample consists of adult pregnant and postpartum women (with infants up to 6 months of age). The assessment includes measures on COVID-19 epidemiology and public health measures (Oxford COVID-19 Government Response Tracker dataset), Coronavirus Perinatal Experiences (COPE questionnaires), psychological distress (BSI-18), depression (EPDS), anxiety (GAD-7) and post-traumatic stress symptoms (PTSD checklist for DSM-V). Discussion: This study will provide important information for understanding the impact of the COVID-19 pandemic on perinatal mental health and well-being, including the identification of potential risk and protective factors by implementing predictive models using machine learning techniques. The findings will help policymakers develop suitable guidelines and prevention strategies for perinatal mental health and contribute to designing tailored mental health interventions. Trial registration: ClinicalTrials.gov Identifier: NCT04595123.The project is part of the COST Action Riseup-PPD CA 18138 and was supported by COST under COST Action Riseup-PPD CA18138; also, by the Spanish Ministry of Health, the Institute of Health Carlos III, and the European Regional Development Fund «Una manera de hacer Europa» by the Prevention and Health Promotion Research Network ‘redIAPP’ (RD16/0007). Raquel Costa is supported by the FSE and FCT under an individual Post-Doctoral Grant SFRH/BPD/117597/2016. Rena Bina and Drorit Levy received funding from the Bar-Ilan Dangoor Centre for Personalized Medicine, Israel. Ana Mesquita is supported from the Portuguese Foundation for Science and Technology (FCT) and from EU through the European Social Fund and from the Human Potential Operational Program - IF/00750/2015. Ana Osório received financial support from CAPES/Proex no. 0653/2018 and CAPES/PrInt grant no. 88887.310343/2018-00.The funders of the study had no role in the study design or the writing the protocol. The corresponding author had final responsibility for the decision to submit for publication

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo

Background: Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride synthesis and free fatty acid mobilization, manifesting decreases in both plasma triglycerides and free fatty acids. In clinical trials, morning administration of Cycloset™ either as monotherapy or adjunctive therapy to sulfonylurea or insulin reduces HbA1c levels relative to placebo by 0.55–1.2. Cycloset™ therapy also reduces plasma triglycerides and free fatty acid by approximately 25% and 20%, respectively, among those also receiving sulfonylurea therapies. The effects of once-daily morning Cycloset™ therapy on glycemic control and plasma lipids are demonstrable throughout the diurnal portion of the day (7 a.m. to 7 p.m.) across postprandial time points. Methods/Design: 3,095 individuals were randomized in a 2:1 ratio into a one year trial aimed to assess the safety and efficacy of Cycloset™ compared to placebo among individuals receiving a variety of treatments for type 2 diabetes. Eligibility criteria for this randomized placebo controlled trial included: age 30–80, HbA1c ≤ 10%, diabetes therapeutic regimen consisting of diet or no more than two hypoglycemic agents or insulin with or without one additional oral agent (usual diabetes therapy; UDT). The primary safety endpoint will test the hypothesis that the rate of all-cause serious adverse events after one year of usual diabetes therapy (UDT) plus Cycloset™ is not greater than that for UDT plus placebo by more than an acceptable margin defined as a hazard ratio of 1.5 with a secondary endpoint analysis of the difference in the rate of serious cardiovascular events, (myocardial infarction, stroke, coronary revascularization or hospitalization for or angina or congestive heart failure). Efficacy analyses will evaluate effects of Cycloset™ versus placebo on change from baseline in HbA1c, fasting glucose, body weight, waist circumference, blood pressure and plasma lipids. Discussion: This study will extend the current data on Cycloset™ safety, tolerability and efficacy in individuals with type 2 diabetes to include its effects in combination with thiazolodinediones, insulin secretagogues, metformin, alpha-glucosidase inhibitors and exogenous insulin regimens. Trial registration: clinical trials.gov NCT0037767